| 000 | 01533cam a2200289 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032026.0 | ||
| 008 | 180801s2017 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.34.M.Sc.2017.Al.D | ||
| 100 | 0 | _aAlaa Rizk Sanad Ibrahim Leila | |
| 245 | 1 | 0 |
_aDesign , synthesis of symmetric molecules as potential anti-HCV agents / _cAlaa Rizk Sanad Ibrahim Leila ; Supervised Ashraf H. Abadi , Mohammad Abdelhalim |
| 246 | 1 | 5 | _aتصميم وتحضير الجزيئات المتماثلة المضادة لفيروس سي |
| 260 |
_aCairo : _bAlaa Rizk Sanad Ibrahim Leila , _c2017 |
||
| 300 |
_a101 Leaves : _bcharts , facsimiles ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceutical Chemistry | ||
| 520 | _aUntil recently, the standard therapy for HCV treatment has been a combination of interferon Ü (IFNÜ) and ribavirin (RBV) which has severe side effects and contraindications. Cure rates reported for this combination therapy were about 50%¹{u⁰⁶⁶B}² therefore, direct-acting antivirals (DAAs) were developed to target viral proteins that are crucial for the HCV lifecycle | ||
| 700 | 0 |
_aAshraf H. Abadi , _eSupervisor |
|
| 700 | 0 |
_aMohammad Abdelhalim , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c66916 _d66916 |
||